Combined treatment with DPP4 inhibitors and SGLT2 inhibitors is an attractive option given their complementary mechanisms of action and the demonstrated effectiveness and tolerability of the combination in patients with T2DM [10, 11]. Here, SLC5A2 is linked to type 2 diabetes mellitus.